A new wave of concern has emerged as fresh COVID-19 subvariants — NB.1.8.1 and LF.7 — have been detected in India. Reports indicate an increased risk of infection in Delhi, with confirmed cases also in Gujarat and Tamil Nadu.
These are subvariants of the JN.1 lineage, which in turn originates from the Omicron BA.2.86 variant.
The subvariants contain mutations in the spike protein such as A435S, V445H, and T478I, making them:
More transmissible, and
Better able to evade immunity.
These variants have also been detected in countries like the USA, Japan, South Korea, France, Thailand, and more.
In China and Hong Kong, they have contributed to rising case numbers, especially among air travelers.
NB.1.8.1: First detected in Tamil Nadu (April 2025)
LF.7: Four cases found in Gujarat (May 2025)
Other states like Delhi, Maharashtra, and Karnataka are also seeing a rise in COVID cases, according to INSACOG (Indian SARS-CoV-2 Genomics Consortium).
As of now, NB.1.8.1 and LF.7 are categorized as Variants Under Monitoring (VUM).
They are not yet classified as Variants of Concern (VOC) or Variants of Interest (VOI).
The World Health Organization (WHO) says the situation is under control as long as hospitalization or death rates don’t spike.
The symptoms are largely similar to other Omicron variants:
Fever, sore throat, runny nose, dry cough
Fatigue, headache, muscle aches
In some cases: diarrhea, loss of appetite, nausea, vomiting
Diarrhea is reported more commonly in JN.1 and its subvariants.
Most vaccinated individuals recover within 4 to 5 days.
Elderly people and immunocompromised individuals should stay cautious.
Healthy lifestyle, balanced diet, and booster doses are recommended.
If symptoms appear, get tested via RT-PCR or rapid antigen test.
If positive, isolate at home and follow medical advice.
Topic | Details |
---|---|
Subvariants | NB.1.8.1 and LF.7 |
Lineage | Sub-lineages of Omicron JN.1 (BA.2.86) |
Cases in India | Total 5 (4 in Gujarat, 1 in Tamil Nadu) |
WHO Category | Variants Under Monitoring (VUM) |
Symptoms | Fever, sore throat, fatigue, diarrhea |
Risk Level | Low but under surveillance |
Recommendation | Stay alert, test early, get booster |